Miami, FL – June 1, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on AXIM(R) Biotechnologies, Inc. (OTCQB: AXIM).

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. Axim Biotechnologies, Inc.

Average daily volume for AXIM 400 thousand shares. Today’s news has caused the volume to increase to over 427 thousand shares in the morning hours of trading.

AXIM(R) Biotechnologies, Inc. Press Release:

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) — AXIM(R) Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM(R) Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has started pre-clinical animal drug studies on its new compound, SPX-1009.

“We look forward to the next step in the race to finding a cure for cancer,” said John W. Huemoeller II, Chief Executive Officer of AXIM(R) Biotech. “After very positive in vitro studies, this pharmacokinetic animal study will tell us whether we have a potential drug candidate for humans. Because it is an analog of a drug that has already completed animal studies, we expect positive results.”

Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme that is over-expressed by tumor cells in numerous cancers, has been shown to be involved in cancer invasion and metastasis. Earlier this year, Sapphire acquired exclusive license rights to a small molecule, SBI-183. SBI-183 has been proven to inhibit the enzymatic activity of QSOX1 and suppress tumor cell invasion in vitro and metastasis of MDA-MB-231 breast tumor cells in vivo. SBI-183 also suppressed human xenograft primary kidney tumor growth by 86 percent compared to controls.

Sapphire scientists have generated and tested over 90 analogs of SBI-183 and discovered that one analog, SPX-1009, was tenfold more potent than SBI-183 in suppressing tumor invasion and metastasis in vitro. Further testing revealed that SPX-1009 suppressed invasion of breast, kidney and pancreas tumor cells in 2D and 3D invasion assays at tenfold lower concentrations than the parent compound SBI-183.

Oral and intravenous therapy (IV) formulations of SPX-1009 are being tested in pharmacokinetic animal studies to determine the optimal route of treatment.

“We are hopeful that SPX-1009 will block metastasis in patients which, after all, is what causes death in the vast majority of cancer patients, ” said Catalina Valencia, Chief Executive Officer of Sapphire Biotech.

For more information about AXIM, please visit www.aximbiotech.com.

About AXIM(R) Biotechnologies

Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses and new cannabinoid molecules for oncological therapeutics.

Currently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. For more information, please visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM(R) Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM(R) Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer CMW Media

P. 858-264-6600

andrew.hard@cmwmedia.com

www.cmwmedia.com

Corporate Contact Info:

6191 Cornerstone Ct., Ste. 114

San Diego, CA 92121, USA

P. 858-999-0920

Investor Relations Contact:

investors@aximbiotech.com

888-759-0844 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  EmergingGrowth.com, or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, http://emerginggrowth.com/disclosure/. Please consult an investment professional before investing in anything viewed within this article or any other portion of EmergingGrowth.com. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments